Helsinn Healthcare S.A. v. Hospira, Inc.

I'll research this case thoroughly before writing.

Now let me pin down the specific D. Del. Hospira docket and its IPR/parallel-proceeding history.

Let me pull the full docket and check for any Hospira PTAB challenges and market context.

Case Overview — Helsinn Healthcare S.A. v. Hospira, Inc., C.A. No. 1:15-cv-00264-GMS (D. Del.)

Parties and what they do. Helsinn Healthcare S.A. is a privately held Swiss pharmaceutical company headquartered in Lugano that develops and licenses supportive-care oncology drugs; its U.S. commercial hub sits in New Jersey. Roche Palo Alto LLC — successor to Syntex, which did the original palonosetron chemistry — was named as a co-plaintiff because the Aloxi patents issued to Helsinn and Roche as assignees. Hospira, Inc. is the Lake Forest, Illinois injectable-drugs and infusion-technology company (spun out of Abbott in 2004, and acquired by Pfizer in a deal announced February 2015 and closed September 2015) that filed ANDA No. 207005 for generic 0.25 mg/5 mL and 0.075 mg/1.5 mL palonosetron hydrochloride IV solutions — a generic copy of Helsinn's Aloxi®. This is a classic Hatch-Waxman, operating-company-versus-generic case, not an NPE/PAE assertion: both sides are (or were) commercial drug companies, and Roche was a co-owner of the patent family rather than a pure licensor. Hospira answered and counterclaimed for declaratory judgment of invalidity on June 8, 2015 (D.I. 7); Roche Palo Alto was later terminated from the case in August 2016 (party record, CourtListener).

Accused product and patents. The accused conduct is Hospira's Paragraph IV certification and § 271(e)(2) artificial infringement via ANDA No. 207005, targeting both the CINV dose (0.25 mg/5 mL) and the PONV dose (0.075 mg/1.5 mL) of generic Aloxi. The complaint as filed asserted the whole Aloxi Orange Book family — U.S. Patent Nos. 7,947,724, 7,947,725, 7,960,424, 8,598,219 and 8,729,094, all titled "Liquid Pharmaceutical Formulations of Palonosetron" and all claiming priority to a January 30, 2003 provisional (see the substantially identical New Jersey complaint, D.N.J. No. 3:15-cv-02077, D.I. 1; JD Supra court report). The patent flagged in this case's metadata is the '725 alone; its claim 2 (which the Federal Circuit treated as representative of the '724/'725/'424 group) covers a stable aqueous solution of 0.05 mg/mL palonosetron HCl, pH 4.5–5.5, 0.005–1.0 mg/mL EDTA, and 10–80 mg/mL mannitol — i.e., the buffered, EDTA-stabilized, mannitol-tonicity-adjusted 5 mL vial formulation that became Aloxi. Note the discrepancy: docket/patent databases list five asserted patents, while the catalog metadata for this case lists only the '725; I could not locate a docket entry formally narrowing the case to the '725, because the case was stayed before any narrowing.

Posture and venue. Filed March 25, 2015 in Wilmington and assigned to Judge Gregory M. Sleet (D. Del. is a magnet venue for ANDA litigation because of its deep Hatch-Waxman docket and experienced bench). Critically, this Delaware suit was a protective second filing: Helsinn had filed the same case against Hospira two days earlier in the District of New Jersey (No. 3:15-cv-02077), its home forum, and filed in Delaware to preserve the 30-month stay in case New Jersey dismissed for lack of personal jurisdiction. Helsinn then moved to stay its own Delaware case (D.I. 19), and Judge Sleet granted the stay on February 19, 2016 (D.I. 36), "pending resolution of the Motion to Dismiss in the New Jersey action," while noting that forum-shopping concerns were "not unfounded" (Richards, Layton & Finger summary; CourtListener docket). The New Jersey court (D.N.J. Apr. 5, 2016, 2016 WL 1338601) then denied Hospira's Rule 12(b)(2)/(b)(6) motions, holding specific jurisdiction existed under Acorda because Hospira's marketer/distributor Hospira Worldwide would sell generic Aloxi in New Jersey (Justia opinion). The Delaware case never reached claim construction, expert discovery, or trial: after a "good-faith final settlement agreement," Helsinn stipulated to dismissal without prejudice under Rule 41(a)(1)(A)(ii), and Judge Sleet so ordered it on September 11, 2018 (D.I. 40–41), with the court retaining jurisdiction to enforce the settlement (D.I. 41).

Why it is notable. First, its timing: the Delaware dismissal came 16 months after the Federal Circuit, in the parallel Teva appeal, held claim 2 of the '725 (among others) invalid under the on-sale bar based on Helsinn's 2001 license and supply agreements with MGI Pharma, Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017) — so Hospira's settlement landed in the window after that affirmance but before the Supreme Court's January 22, 2019 decision in Helsinn v. Teva, 586 U.S. 123 (2019), which unanimously held that the AIA did

I'll research this case across the docket, court opinions, Federal Circuit, and PTAB.

Helsinn Healthcare S.A. v. Hospira, Inc., No. 1:15-cv-00264-GMS (D. Del.) — Litigation Chronology

Bottom line: This was a thin, 42-entry docket that never reached the merits. It was a protective "second-filed" Hatch-Waxman suit filed to preserve the 30-month FDA stay while Helsinn's first-filed New Jersey action against Hospira was subject to a jurisdictional challenge. Judge Sleet stayed it on 2016-02-19, roughly eleven months after filing; the case then sat dormant for ~2.5 years and was dismissed without prejudice on 2018-09-11 pursuant to a confidential settlement. No Markman, no summary judgment, no trial, no judgment, no appeal from this case. The substantive rulings on the '725 patent came from the parallel D.N.J. litigation and the resulting Federal Circuit / Supreme Court appeals.

---

1. Filing and initial pleadings

2015-03-25 — Complaint filed (D.I. 1). Helsinn Healthcare S.A. and Roche Palo Alto LLC sued Hospira, Inc. in D. Del., assigned to Judge Gregory M. Sleet as C.A. No. 15-264-GMS. Cause: 35 U.S.C. § 271(e)(2) ANDA infringement. The action targeted Hospira's ANDA No. 207005, seeking approval for generic 0.25 mg/5 mL and 0.075 mg/1.5 mL palonosetron hydrochloride IV solutions (generic Aloxi®) with a Paragraph IV certification.

Patents at issue. The docket and the parallel N.J. complaint reflect the same five Orange Book-listed patents: 7,947,724; 7,947,725; 7,960,424; 8,598,219; 8,729,094 (D.I. 4, Report to Commissioner). The case metadata for this matter lists only the '725, which is the representative claim family member (claim 2 of the '725 was later designated the representative claim in the Federal Circuit appeal) and the patent at the center of the Supreme Court's Helsinn decision. Note the discrepancy between the metadata and the five-patent docket.

2015-06-08 — Hospira's Answer and Counterclaims (D.I. 7). Hospira asserted counterclaims against Helsinn and Roche. The docket description does not enumerate the counts; given the posture (Paragraph IV ANDA defense), they would conventionally be declaratory-judgment counts of invalidity and non-infringement — I could not confirm the specific counts from the sources retrieved, so treat the subject matter of the counterclaims as unverified.

2015-06-17 → 2015-11-13 — Serial extensions, then reply to counterclaims. Helsinn/Roche obtained four successive extensions to respond to Hospira's counterclaims (D.I. 9, 10, 11, 12, 16), finally answering on 2015-11-13 (answer to D.I. 7). The pattern of extensions is itself strategically telling: the plaintiffs were not driving this case.

2015-09-29 — Order Regarding Case Management (Sleet, J.). Standard form order only. No Rule 16 scheduling order was ever entered, and no discovery plan, protective order, or ESI order appears on the docket.

---

2. Pre-trial motions of substance

Late 2015 — Helsinn's Motion to Stay the Second-Filed Delaware Case (D.I. 19). Unusually, the plaintiff moved to stay its own case, on first-to-file grounds: the same ANDA and the same patents were already at issue in Helsinn Healthcare S.A. v. Hospira, Inc., No. 15-2077 (D.N.J.), where Hospira had moved to dismiss for lack of personal jurisdiction and for failure to state a claim. The Delaware suit was a "protective measure" filed inside the 45-day window solely to preserve the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii) in case New Jersey dismissed.

• Hospira opposed (answering brief D.I. 25, declaration D.I. 26, both later filed under seal/redacted at D.I. 27–28), arguing forum shopping and that the first-to-file rule should not apply where the first court's jurisdiction was contested.
• Helsinn replied (D.I. 30–32, 2016-01-07), with a declaration from Young J. Park.
• 2016-01-15 — Joint status report (D.I. 35) filed while the stay motion was pending.

2016-02-19 — Stay granted (D.I. 36). Judge Sleet granted the motion and stayed the matter "pending resolution of the Motion to Dismiss in the New Jersey action." Per the Richards, Layton & Finger case note, the court found Helsinn's forum-shopping concerns "not unfounded" (i.e., some prejudice to Hospira) but was persuaded by (i) the waste of parallel proceedings, (ii) the early stage, and (iii) Helsinn's representation that it would move to transfer the Delaware case to New Jersey if the N.J. motion to dismiss was denied.

No other substantive pretrial motion was filed in Delaware — no motion to dismiss, no § 1404(a) transfer motion, no stay pending IPR, no summary judgment, no Daubert motion. The case was frozen before

I'll research the counsel of record for Helsinn Healthcare in this Delaware action.

Let me dig into the actual docket and filings.

Now let me verify the complaint signature block and pro hac vice admissions in the Delaware case.

Counsel of Record for Plaintiff Helsinn Healthcare S.A. — Helsinn Healthcare S.A. v. Hospira, Inc., No. 1:15-cv-00264-GMS (D. Del.)

Context that shapes the roster: this Delaware action was Helsinn's second-filed, protective case. Helsinn filed the same five Aloxi® patents ('724, '725, '424, '219, '094) against Hospira in D.N.J. (No. 15-2077) on March 23, 2015 — two days before this Delaware complaint — and then moved to stay the Delaware case (D.I. 19) pending the New Jersey Rule 12 motion. Judge Sleet granted the stay on Feb. 19, 2016 (D.I. 36), and the case sat dormant until it was dismissed without prejudice on Sept. 11, 2018 (D.I. 40–41). Consequently, only a small handful of attorneys ever entered an appearance here; the deep bench sat on the New Jersey docket.

Delaware counsel of record (all Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE)

Non-Delaware counsel appearing of record

Helsinn's national trial/appellate team (same Aloxi® case family — not confirmed on the Delaware docket)

These lawyers are Helsinn's lead Hatch-Waxman counsel in the parallel D.N.J. consolidated palonosetron litigations (Nos. 11-3962, 15-2077, 15-7015, 15-7378 (MLC)(DEA)) and on the Federal Circuit/Supreme Court papers. I found no Delaware appearance by any of them in 15-264, so I list them for completeness rather than as counsel of record here:

• Charles M. Lizza — Saul Ewing LLP (now Saul Ewing Arnstein & Lehr LLP), One Riverfront Plaza, Newark, NJ. Helsinn's chief ANDA/Hatch-Waxman litigator across the Aloxi® program; signed the D.N.J. complaints, the Rule 11.2/40.1 related-case certifications, and the Helsinn v. Teva cert petition.
• William C. Baton — Saul Ewing LLP, Newark, NJ. Co-counsel with Lizza on the D.N.J. Aloxi® matters and the Federal Circuit appeal (No. 16-1284).
• Joseph M. O'Malley, Jr. and Eric W. Dittmann — Paul Hastings LLP, New York, NY. Helsinn's national IP counsel on the Aloxi® complaints and the cert petition.
• Mark E. Waddell — Loeb & Loeb LLP, 345 Park Avenue, New York, NY. Represented co-plaintiff Roche Palo Alto LLC, which was terminated from this case on Aug. 8, 2016 (D.I. 38–39) after assigning its rights to Helsinn.

Caveats and sourcing

• No in-house counsel for Helsinn appears of record in this action; no corporate counsel signature block was located.
• The CourtListener parties page for this docket (docket no. 8206976) was partially truncated in my search results, so I cannot rule out one or two additional pro hac vice appearances that were never reflected in a filing I could retrieve. The docket sheet itself (via PACER) is the definitive check; the Delaware case's short active life makes a large shadow docket unlikely.
• Nothing here was sealed in a way that obscured counsel — the plaintiff-side filings I cite (D.I. 10, 19, 20, 29, 31, 33, 34, 35, 38, 40) are all public; the sealed items (D.I. 30, 32) were exhibits/briefs, not appearances.
• One note on the case metadata: the prompt lists only the '725 patent as at issue, but the Delaware complaint asserted five patents ('724, '725, '424, '219, '094), consistent with the parallel Hospira ANDA No. 207005 challenge.

Sources: CourtListener docket and parties pages for Helsinn Healthcare S.A. v. Hospira Inc., No. 1:15-cv-00264 (D. Del.) (https://www.courtlistener.com/docket/8206976/helsinn-healthcare-sa-v-hospira-inc/); CourtListener RECAP PDFs from the related D.N.J. actions (Nos. 3:15-cv-02077, 3:15-cv-07378); Helsinn cert petition, Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc. (Feb. 2018), http://patentlyo.com/media/2018/03/Helsinn-cert-petition-17-xxx.pdf; Roche Palo Alto LLC's Unopposed Motion to Withdraw, Fed. Cir. No. 16-1284 (May 16, 2016); Thomson Reuters/vitallaw IP Law Daily, "PATENT—D.N.J.: Helsinn could pursue ANDA-based infringement action in New Jersey" (Apr. 6, 2016).

I'll research the docket and counsel for Hospira in this case.

Let me pull the full docket and the answer/counterclaim signature blocks.

I need the signature blocks on Hospira's answer and briefs. Let me pull those documents.

Counsel of record for Defendant Hospira, Inc.

Bottom line: Only two attorneys appear on the public docket as counsel of record for Hospira in D. Del. C.A. No. 1:15-cv-00264, both Delaware local counsel — Dominick T. Gattuso (Heyman Enerio Gattuso & Hirzel LLP), who was Hospira's attorney of record for essentially the whole life of the case, and Mary B. Matterer (Morris James LLP), who appeared initially and was substituted out in October 2015. I could not verify from any public source a national/lead trial counsel appearing pro hac vice for Hospira in this Delaware docket (see caveats below), so I am not naming one.

Docket anchors

• D.I. 7 (June 8, 2015) — "ANSWER to 1 Complaint, COUNTERCLAIM against Helsinn Healthcare S.A., Roche Palo Alto LLC by Hospira Inc. … (Matterer, Mary)" — Hospira's first appearance of record.
• D.I. 8 (filed 10/15/2015, entered 10/16/2015) — "NOTICE OF SUBSTITUTION OF COUNSEL re Hospira Inc.: Entry of appearance of attorney Dominick T. Gattuso. Attorney Mary B. Matterer terminated."
• D.I. 25–28 (Dec. 2015–Jan. 2016) — Hospira's sealed answering brief opposing Helsinn's motion to stay, its supporting Declaration of Dominick T. Gattuso, and redacted versions — all Hospira filings were made through Gattuso.
• D.I. 38 (Aug. 2016) — stipulation of dismissal as to Roche Palo Alto LLC; D.I. 40–41 (Sept. 11, 2018) — stipulation of dismissal without prejudice, so ordered; case terminated 9/11/2018.
• CourtListener parties page: https://www.courtlistener.com/docket/8206976/parties/helsinn-healthcare-sa-v-hospira-inc/

Caveats / what I could not verify

1. No pro hac vice admissions for Hospira-side counsel appear in the public docket. The only pro hac vice motion indexed in this case is Plaintiff-side (D.I. 29, Young J. Park). The litigation was concentrated in the parallel New Jersey action (Helsinn Healthcare S.A. v. Hospira, Inc., D.N.J. No. 3:15‑cv‑02077‑MLC) and this Delaware case — Helsinn's second-filed suit — was stayed in February 2016 pending the New Jersey motion to dismiss, then dismissed by stipulation in 2018. That posture explains the thin Delaware-side defense roster: no trial-team pro hac vice entries were ever necessary here.
2. Hospira's national/lead Hatch‑Waxman counsel in this matter is not evidenced on this docket. Hospira's principal outside patent litigation firm in contemporaneous matters was Willkie Farr & Gallagher LLP (Thomas J. Meloro, Michael W. Johnson, New York) — documented in Amgen v. Hospira, D. Del. No. 1:15‑cv‑00839‑RGA, and in a 2021 Pfizer/Hospira D. Del. transcript where Willkie attorneys appeared alongside Mr. Gattuso. I found no filing in 1:15‑cv‑00264 naming Willkie (or any other national firm) for Hospira, so I am not representing that they were counsel of record here. If the Answer (D.I. 7) or the Dec. 2015 briefs carry a national-firm signature block, it is not reflected in the public docket text I could access.
3. In-house counsel: no Hospira in-house attorney appears on this docket; I have not identified one and will not guess.
4. Sealed material: Hospira's stay opposition and supporting declaration (D.I. 25, 26) were filed under seal (redacted versions at D.I. 27, 28); any additional counsel named only inside those sealed papers would not be visible publicly.

If you want the national-firm roster confirmed, the fastest paths are (a) pulling the full PDF of D.I. 7 and D.I. 25 from PACER/RECAP for the signature blocks, or (b) checking the D.N.J. 3:15‑cv‑02077 docket, where Hospira's lead trial team would have moved pro hac vice.